Key facts
- Red Queen Bio’s last known valuation is $56.0M (Nov 2025).
- It has raised $15.0M; the latest was Seed Round ($15.0M) in Nov 2025.
- Notable investors include Gaingels, Fifty Years, Dhuna Ventures, Compound (New York), OpenAI — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Red Queen Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Red Queen Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Red Queen Bio
Developer of biosecurity technology designed to defend against emerging biological threats enabled by artificial intelligence proactively. The company works with frontier laboratories to map AI-enabled biothreats and pre-build medical countermeasures, leveraging advanced computational models, lab automation, reinforcement learning, and on-demand biologics manufacturing, enabling the global biopharma industry and governments to scale defensive capabilities alongside technological advances.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2025
- Website
- redqueen.bio/
- Ownership
- Privately Held (backing)
Red Queen Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Red Queen Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Red Queen Bio in its N-PORT filings yet. We sweep new filings monthly.